<DOC>
	<DOCNO>NCT01751919</DOCNO>
	<brief_summary>1 . Investigational Product 1 . Imatinib mesylate tablet 400 mg 2 . Glivec film-coated tablet 100 mg ( Comparator ) 2 . Expected target disease 1. chronic myeloid leukemia 2 . Gastrointestinal stromal tumor 3 . Study design : Randomized , open-label , single dose , two-period , two-way , crossover study 1 . 36 healthy subject , 2 group ( 18 subjects/group ) 2 . 2 Period ( either 1-a ( 1 tablet ) 1-b ( 4 tablet ) ) 3. wash-out period : 14 day 4 . Evaluation pharmacokinetics ( PKs ) safety 1 . PKs : Cmax , AUClast , Tmax , AUCinf , t1/2 2. safety : adverse event , physical examination , vital sign , ECG , Laboratory test 5 . Statistical method 1 . Demography Characteristics 2 . Pharmacokinetic parameter 3 . Safety data</brief_summary>
	<brief_title>A Clinical Trial Compare Pharmacokinetics Imatinib Mesylate Tablet 400mg ( 1 Tablet ) Glivec Film-coated Tablet 100mg ( 4 Tablets ) ( Phase I )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>healthy male volunteer age 20 50 year old weight 55kg within range Â±20 % ideal body weight ( IBW ) neither congenital/chronic disease pathological symptoms/findings result medical examination doctor determine suitable subject within 3 week ago administration Hypersensitivity ( history hypersensitivity ) medicine include imatinib mesylate Active Liver Diseases exceed 1.5 time normal range AST , ALT , total bilirubin Creatinine clearance &lt; 80 mL/min Gastrointestinal disease surgery affect absorption drug Excessive drinking ( exceed 21units/week ) Smoking 10 cigarette per day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>CML</keyword>
	<keyword>GIST</keyword>
</DOC>